Xcout IntelPrime Medicine, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Prime Medicine, Inc. among biotechnology companies — ranked by similarity to what Prime Medicine, Inc. actually does, not by market-cap band.
Subscribe to see Prime Medicine, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Prime Medicine, Inc.
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
Prime Medicine, Inc. at a glance
Prime Medicine, Inc. is a biotechnology company headquartered in Cambridge, United States. It is publicly listed (PRME) with a market capitalisation of $720.7M. Xcout tracks 27 named people at Prime Medicine, Inc., including Allan Reine (Chief Executive Officer & Director). Xcout recorded 19 job postings from Prime Medicine, Inc. in the last 90 days, naming tools such as LangChain, LangGraph.
Prime Medicine, Inc. leadership
- Allan ReineChief Executive Officer & Director
- Svetlana MakhniChief Financial Officer
- Ann L. LeeChief Technical Officer
- Ann LeeChief Technical Officer
- Matthew J. HawrylukChief Business Officer
- Matthew HawrylukChief Business Officer
21 more named people on record for Prime Medicine, Inc., with roles, board committees and tenure — see the full roster →
Hiring at Prime Medicine, Inc.
Xcout recorded 19 job postings from Prime Medicine, Inc. in the last 90 days, from a hiring record Xcout has kept since June 2026.
Tools named in Prime Medicine, Inc.'s job postings
The weekly hiring trend, the roles and locations behind it — see Prime Medicine, Inc.'s hiring signals →
Top 12 Prime Medicine, Inc. competitors
Ranked by semantic similarity — how close each company is to Prime Medicine, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Verve Therapeutics, Inc. is a biotechnology company headquartered in Boston, Massachusetts, dedicated to pioneering single-course gene editing medicines for cardiovascular disease.
Similar biotechnology company
KOMO Biosciences is a biotechnology research company headquartered in Cambridge, Massachusetts. The company specializes in next-generation precision genome engineering driven by highly efficient, evolved integrases.
Similar biotechnology company
Base Therapeutics is a biotechnology company that develops next-generation gene editing technologies, including its proprietary AccuBase base editing system and enhanced prime editing technology. The company focuses on creating therapeutic solutions for cancer and genetic diseases, alongside engineered immune cell therapies such as BASE-NK and CAR-T products. It serves patients and partners with pharmaceutical and agricultural enterprises by licensing its precision gene editing tools.
Biotech
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Biotech
Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These treatments are formulated through RNA editing technology, aiming to address a wide array of medical conditions, encompassing both uncommon and widespread diseases.
Similar biotechnology company
Carmine Therapeutics, Inc. is an EVX Ventures company headquartered in Cambridge, Massachusetts, focused on developing novel gene therapies.
Similar biotechnology company
Exsilio Therapeutics Inc. is a biotechnology company headquartered in Boston, Massachusetts, founded in 2022 to pioneer genomic medicines and advanced genetic therapies.
Similar biotechnology company
Houdini Bio is a biotechnology company headquartered in London, United Kingdom, with operations in Cambridge. The firm focuses on genetic medicine to unlock its full therapeutic potential and advance curative treatments.
Similar biotechnology company
Arbor Biotechnologies, Inc. is a next-generation gene editing company focused on discovering and developing precise genetic medicines for rare and complex diseases.
Similar biotechnology company
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
Biotech
Azalea Therapeutics is a biotechnology company headquartered in Berkeley, California. The company focuses on precision genome engineering directly inside the body with an initial emphasis on developing in vivo cancer immunotherapies.
Similar biotechnology company
Kelonia Therapeutics, Inc. is a clinical-stage biotech company headquartered in Boston, Massachusetts, focused on delivering genetic medicine for patients.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Prime Medicine, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Prime Medicine, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →